BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 15480402)

  • 1. Bisphosphonates for the treatment of Charcot neuroarthropathy.
    Anderson JJ; Woelffer KE; Holtzman JJ; Jacobs AM
    J Foot Ankle Surg; 2004; 43(5):285-9. PubMed ID: 15480402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial.
    Jude EB; Selby PL; Burgess J; Lilleystone P; Mawer EB; Page SR; Donohoe M; Foster AV; Edmonds ME; Boulton AJ
    Diabetologia; 2001 Nov; 44(11):2032-7. PubMed ID: 11719835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates: a new treatment for diabetic Charcot neuroarthropathy?
    Selby PL; Young MJ; Boulton AJ
    Diabet Med; 1994; 11(1):28-31. PubMed ID: 8181248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurement of markers of osteoclast and osteoblast activity in patients with acute and chronic diabetic Charcot neuroarthropathy.
    Gough A; Abraha H; Li F; Purewal TS; Foster AV; Watkins PJ; Moniz C; Edmonds ME
    Diabet Med; 1997 Jul; 14(7):527-31. PubMed ID: 9223389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical treatment of Charcot neuroosteoarthropathy.
    Jostel A; Jude EB
    Clin Podiatr Med Surg; 2008 Jan; 25(1):63-9, vi-vii. PubMed ID: 18165112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Charcot arthropathy successfully treated with pamidronate: long-term follow-up.
    Naqvi A; Cuchacovich R; Saketkoo L; Espinoza LR
    Am J Med Sci; 2008 Feb; 335(2):145-8. PubMed ID: 18277124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Charcot neuro-osteoarthropathy-current standards.
    Petrova NL; Edmonds ME
    Diabetes Metab Res Rev; 2008; 24 Suppl 1():S58-61. PubMed ID: 18442182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Charcot neuroarthropathy in diabetes mellitus.
    Rajbhandari SM; Jenkins RC; Davies C; Tesfaye S
    Diabetologia; 2002 Aug; 45(8):1085-96. PubMed ID: 12189438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Surgeon's guide to advances in the pharmacological management of acute Charcot neuroarthropathy.
    Al-Nammari SS; Timothy T; Afsie S
    Foot Ankle Surg; 2013 Dec; 19(4):212-7. PubMed ID: 24095226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta.
    DiMeglio LA; Ford L; McClintock C; Peacock M
    Bone; 2004 Nov; 35(5):1038-45. PubMed ID: 15542028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The perils of procrastination: effects of early vs. delayed detection and treatment of incipient Charcot fracture.
    Chantelau E
    Diabet Med; 2005 Dec; 22(12):1707-12. PubMed ID: 16401316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acellular fetal bovine dermal matrix for treatment of chronic ulcerations of the midfoot associated with Charcot neuroarthropathy.
    Kavros SJ
    Foot Ankle Spec; 2012 Aug; 5(4):230-4. PubMed ID: 22715495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget's disease of bone.
    Martini G; Gennari L; Merlotti D; Salvadori S; Franci MB; Campagna S; Avanzati A; De Paola V; Valleggi F; Nuti R
    Bone; 2007 Feb; 40(2):457-63. PubMed ID: 16979395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of zoledronic acid on the clinical resolution of Charcot neuroarthropathy: a pilot randomized controlled trial.
    Pakarinen TK; Laine HJ; Mäenpää H; Mattila P; Lahtela J
    Diabetes Care; 2011 Jul; 34(7):1514-6. PubMed ID: 21593295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healing of Charcot's joint by pamidronate infusion.
    Guis S; Pellissier JF; Arniaud D; Turck F; Witjas T; Roux H; Mattei JP
    J Rheumatol; 1999 Aug; 26(8):1843-5. PubMed ID: 10451089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
    Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
    Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of acute Charcot foot with bisphosphonates: a systematic review of the literature.
    Richard JL; Almasri M; Schuldiner S
    Diabetologia; 2012 May; 55(5):1258-64. PubMed ID: 22361982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetes and acute Charcot neuroarthropathy--a call for heightened vigilance.
    Iheonunekwu N; Ibrahim TM; Ojuro I
    Niger J Med; 2010; 19(2):239-40. PubMed ID: 20642098
    [No Abstract]   [Full Text] [Related]  

  • 19. Renal safety of 1-hour pamidronate infusion for breast cancer and multiple myeloma patients: comparison between clinical trials and population-based database.
    de Lemos ML; Taylor SC; Barnett JB; Hu F; Levin A; Moravan V; O'Reilly SE
    J Oncol Pharm Pract; 2006 Dec; 12(4):193-9. PubMed ID: 17156591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates.
    Farrugia MC; Summerlin DJ; Krowiak E; Huntley T; Freeman S; Borrowdale R; Tomich C
    Laryngoscope; 2006 Jan; 116(1):115-20. PubMed ID: 16481822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.